Literature DB >> 23090011

A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.

Felipe R Lorenzo1, Chunzhang Yang, Mark Ng Tang Fui, Hariprasad Vankayalapati, Zhengping Zhuang, Thanh Huynh, Mathis Grossmann, Karel Pacak, Josef T Prchal.   

Abstract

Congenital polycythemias have diverse etiologies, including mutations in the hypoxia sensing pathway. These include HIF2A at exon 12, VHL gene (Chuvash polycythemia), and PHD2 mutations, which in one family was also associated with recurrent pheochromocytoma/paraganglioma (PHEO/PGL). Over the past two decades, we have studied seven unrelated patients with sporadic congenital polycythemia who subsequently developed PHEO/PGL with, until now, no discernible molecular basis. We now report a polycythemic patient with a novel germline HIF2A (F374Y) (exon 9) mutation, inherited from his mother, who developed PHEO/PGL. We show that this is a gain-of-function mutation and demonstrate no loss-of-heterozygosity or additional somatic mutation of HIF2A in the tumor, indicating HIF2A (F374Y) may be predisposing rather than causative of PHEO/PGL. This report, in view of two other concomitantly reported PHEO/PGL patients with somatic mutations of HIF2A and polycythemia, underscores the PHEO/PGL-promoting potential of mutations of HIF2A that alone are not sufficient for PHEO/PGL development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23090011      PMCID: PMC3570726          DOI: 10.1007/s00109-012-0967-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  23 in total

1.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

Review 2.  HIF-1 and mechanisms of hypoxia sensing.

Authors:  G L Semenza
Journal:  Curr Opin Cell Biol       Date:  2001-04       Impact factor: 8.382

3.  Endemic polycythemia in Russia: mutation in the VHL gene.

Authors:  Sonny O Ang; Hua Chen; Victor R Gordeuk; Adelina I Sergueeva; Lydia A Polyakova; Galina Y Miasnikova; Robert Kralovics; David W Stockton; Josef T Prchal
Journal:  Blood Cells Mol Dis       Date:  2002 Jan-Feb       Impact factor: 3.039

4.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.

Authors:  Zhengping Zhuang; Chunzhang Yang; Felipe Lorenzo; Maria Merino; Tito Fojo; Electron Kebebew; Vera Popovic; Constantine A Stratakis; Josef T Prchal; Karel Pacak
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

5.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.

Authors:  H Tian; S L McKnight; D W Russell
Journal:  Genes Dev       Date:  1997-01-01       Impact factor: 11.361

6.  Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.

Authors:  Yves Pastore; Katerina Jedlickova; Yongli Guan; Enli Liu; James Fahner; Henrik Hasle; Jaroslav F Prchal; Josef T Prchal
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

7.  Structural basis for PAS domain heterodimerization in the basic helix--loop--helix-PAS transcription factor hypoxia-inducible factor.

Authors:  Paul J A Erbel; Paul B Card; Ozgur Karakuzu; Richard K Bruick; Kevin H Gardner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

Review 8.  Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis.

Authors:  Josef T Prchal
Journal:  Hematol Oncol Clin North Am       Date:  2003-10       Impact factor: 3.722

9.  General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.

Authors:  G L Wang; G L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

10.  Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia.

Authors:  R Kralovics; L Sokol; J T Prchal
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

View more
  70 in total

Review 1.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 2.  Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?

Authors:  Lauren Fishbein
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

3.  Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia.

Authors:  Chunzhang Yang; Zhengping Zhuang; Stephanie M J Fliedner; Uma Shankavaram; Michael G Sun; Petra Bullova; Roland Zhu; Abdel G Elkahloun; Peter J Kourlas; Maria Merino; Electron Kebebew; Karel Pacak
Journal:  J Mol Med (Berl)       Date:  2014-09-30       Impact factor: 4.599

4.  Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.

Authors:  Johan Kugelberg; Jenny Welander; Francesca Schiavi; Ambrogio Fassina; Martin Bäckdahl; Catharina Larsson; Giuseppe Opocher; Peter Söderkvist; Patricia L Dahia; Hartmut P H Neumann; Oliver Gimm
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

5.  Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.

Authors:  Ying Pang; Garima Gupta; Abhishek Jha; Xupeng Yue; Herui Wang; Thanh-Truc Huynh; Aiguo Li; Liping Li; Eva Baker; Emily Chew; Richard A Feelders; Esther Korpershoek; Zhengping Zhuang; Chunzhang Yang; Karel Pacak
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

6.  Pheochromocytoma and paraganglioma syndromes: genetics and management update.

Authors:  M Lefebvre; W D Foulkes
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

7.  First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.

Authors:  David Taïeb; Chunzhang Yang; Blandine Delenne; Zhengping Zhuang; Anne Barlier; Fréderic Sebag; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

8.  In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.

Authors:  Rodrigo A Toledo; Yuejuan Qin; Subramanya Srikantan; Nicole Paes Morales; Qun Li; Yilun Deng; Sang-Woo Kim; Maria Adelaide A Pereira; Sergio P A Toledo; Xiaoping Su; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

9.  Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range.

Authors:  Silverio Perrotta; Daniel P Stiehl; Francesca Punzo; Saverio Scianguetta; Adriana Borriello; Debora Bencivenga; Maddalena Casale; Bruno Nobili; Silvia Fasoli; Adriana Balduzzi; Lilla Cro; Katarzyna J Nytko; Roland H Wenger; Fulvio Della Ragione
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 10.  Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.

Authors:  Ales Vicha; Zdenek Musil; Karel Pacak
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-06       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.